Find policies, billing codes, payers, states, and providers
Computed Tomography to Detect Coronary Artery Calcification
Customize your policy alerts
Sign up for Bluecross Idaho Policy MP 6.01.03 alerts
Get alerted when Policy MP 6.01.03 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity and investigational uses of CT coronary artery calcium scoring and AI-based automated CAC analysis for risk assessment in adults; applies to Blue Cross of Idaho benefit plans and informs coverage determinations.
Coronary artery calcium scoring may be considered medically necessary as an adjunct to standard cardiovascular risk assessment in asymptomatic adults without known coronary artery disease or clinical atherosclerotic cardiovascular disease in individuals at least 40 years of age and borderline to intermediate 10-year lipid-lowering therapy (see Policy Guidelines).
Artificial intelligence-based automated detection, quantification, or scoring of coronary artery calcium on chest CT (gated or non-gated) as an adjunct to standard risk assessment is considered investigational.
Computed tomography to detect coronary artery calcification is considered investigational for all other indications.
Coverage Criteria
Medically Necessary Coverage
Covered when ALL of the following are met:
Intended as an adjunct to standard cardiovascular risk assessment
Investigational / Not Covered
Not covered / Investigational:
Policy considers AI-based automated CAC analysis investigational for clinical use despite availability of FDA-cleared devices; AI tools are described as adjunctive to clinician interpretation
Use of CT to detect CAC for other indications may be denied as investigational
Evidence and population criteria
Evaluations and evidence were focused on asymptomatic individuals where CAC scoring is used alongside standard risk stratification.
Derived from study selection criteria and intervention description
Evidence-based contexts and observed effects
Evidence summary and clinical contexts where CAC scoring may be applied:
See Scheu et al (2025) and related RCTs/observational studies
Absence of calcium suggests lower likelihood of CAD and may direct workup to non-atherosclerotic causes
Some trials showed LDL reductions and increased statin use while pooled analyses were heterogeneous
Indications and role
Covered when CAC scoring is used to inform risk stratification or to rule out an atherosclerotic cause in symptomatic individuals:
Supported by observational cohorts, guideline recommendations, and selected trials
Limitations / Cautions
Clinical limitations and situations requiring caution:
Observational studies report obstructive CAD and MACE events despite CAC=0 in symptomatic cohorts
See subgroup findings and study inclusion criteria requiring adequate sample sizes and reference standards
Symptomatic patients - CAC score diagnostic performance
Evidence summary and implications for symptomatic patients:
Examples include Yoon et al, Hulten et al, Gottlieb et al, and Yuan et al demonstrating false-negatives and variable NPV/sensitivity
AI-based CAC detection - performance summaries
AI-based CAC detection performance:
FDA validation data for at least one algorithm met weighted kappa ≥0.90
Supported by multiple studies and FDA submissions
Clinically meaningful misclassification has been reported in some cohorts
Overall coverage conclusion
Evidence summary and coverage stance:
FDA-cleared AI algorithms are indicated as adjunctive tools and not replacements for physician review
CAC testing and interpretation criteria
Guideline-based uses and interpretations of CAC for risk assessment and therapy decisions:
ACC/AHA guideline class IIa/IIb and dyslipidemia guideline recommendations
Derived from guideline recommendations for initiation and intensity of LLT
Guidelines recommend reporting incidental CAC and considering preventive management
Medically Necessary Use
Covered as an adjunct to standard cardiovascular risk assessment:
See Policy Guidelines for detailed risk thresholds and application
Investigational / Not Covered
Not covered / Investigational:
Policy explicitly designates AI-based automated CAC analysis investigational despite FDA 510(k) clearances
Requests for CAC CT outside the covered context may be denied as investigational
This policy may not apply to all lines of business. Benefit exceptions include, but are not limited to, the Federal Employee Program, Medicare Supplement, Medicare Advantage, Medicaid, and certain self‑insured groups. Verify member plan benefits and applicable contract language when making coverage determinations.
When evaluating evidence for clinical validity of coronary artery calcium (CAC) scoring, preference was given to studies that reported on the marketed version of the technology, included a suitable reference standard, described patient/sample clinical characteristics and selection criteria, and reported results on a minimum of 1,000 patients. Studies that did not meet these criteria (eg, small sample size, unspecified reference standard, or unclear selection) were considered insufficient to establish clinical validity.
A chain-of-evidence approach was used: indirect inferences about clinical utility require demonstrable clinical validity. If the evidence is insufficient to show test performance, no reliable inferences about clinical utility can be made. Because clinical validity of CAC scoring in some contexts (notably symptomatic patients) remains unestablished, the chain of evidence for clinical utility in those settings cannot be constructed.
A CAC (Agatston) score of 0 (zero) does not guarantee absence of clinically important coronary artery disease in symptomatic patients. Multiple observational studies have identified patients with a CAC score of 0 who nonetheless had ≥50% stenosis on CCTA or invasive angiography and who experienced major adverse cardiovascular events, so a zero score should not be used in isolation to exclude an atherosclerotic cause in symptomatic individuals.
Evidence is currently insufficient to establish that CAC scoring provides net clinical utility when used as the sole diagnostic gatekeeper in symptomatic patients. Although a CAC score of 0 may have a low negative likelihood ratio in some analyses, inconsistent diagnostic accuracy across studies and lack of randomized evidence mean CAC scoring alone cannot be relied upon to change management or improve patient‑level outcomes in symptomatic populations.
Artificial intelligence (AI) algorithms for detection, quantification, or scoring of coronary artery calcium have demonstrated technical feasibility and, in many datasets, strong agreement with manual expert scoring. However, all currently FDA‑cleared AI CAC algorithms are indicated as adjunctive tools to support, not replace, physician review. The incremental clinical value of AI‑assisted interpretation over manual interpretation has not been established, and clinician oversight remains required.
The U.S. Preventive Services Task Force (USPSTF) reviewed nontraditional risk factors, including coronary artery calcium, and concluded that evidence is insufficient to assess the balance of benefits and harms of adding these nontraditional factors to traditional risk assessment in asymptomatic adults with no known cardiovascular disease.
Computed tomography to detect coronary artery calcification is considered investigational for indications other than the specified adjunctive use in asymptomatic adults age ≥40 with borderline to intermediate 10‑year ASCVD risk. Requests for CT to detect CAC for other indications are therefore not supported by this policy.
Use of CT to detect coronary artery calcification for populations or clinical questions outside the covered adjunctive scenario (asymptomatic adults ≥40 years with borderline‑to‑intermediate 10‑year risk when CAC will inform lipid‑lowering therapy decisions) is not supported by the policy and is considered investigational.
Coding
| JAK | FDA product code for CT devices (example) |
| 75571 | Computed tomography, heart, without contrast material, with quantitative evaluation of coronary calcium. |
| 75572 | Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology (including 3D image postprocessing, assessment of cardiac function, and evaluation of venous structures, if performed). |
| 75573 | Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology in the setting of congenital heart disease (including 3D image postprocessing, assessment of LV cardiac function, RV structure and function, and evaluation of venous structures, if performed). |
| 75574 | Computed tomographic angiography, heart, coronary arteries, and bypass grafts (when present), with contrast material, including 3D image postprocessing (including evaluation of cardiac structure and morphology, assessment of cardiac function, and evaluation of venous structures, if performed). |
| 75577 | Quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, derived from augmentative software analysis of the data set from a coronary computed tomographic angiography, with interpretation and report by a physician or other qualified health care professional. |
| G0680 | Detection and quantification of coronary artery calcium and/or aortic valve calcification from algorithmic analysis of computed tomography of the chest with report. |
| S8092 | Electron beam computed tomography (also known as ultrafast CT, cine CT) — Investigational for all relevant diagnoses. |
| I25.10-I25.119 | Atherosclerotic heart disease of native coronary artery. |
| I25.700-I25.799 | Atherosclerosis of coronary artery bypass graft(s) and coronary artery of transplanted heart with angina pectoris. |
| Z13.6 | Encounter for screening for cardiovascular disorders. |
Bundled with 75572-75574 — Quantitative CAC assessment included when performed with contrast-enhanced cardiac CT/CTA
When quantitative coronary artery calcium (CAC) assessment is performed during the same encounter as contrast‑enhanced cardiac CT (CPT 75572–75573) or coronary CT angiography (CPT 75574), the quantitative CAC assessment is included in that service and should not be billed separately.
Provider Actions & Documentation
PA: Confirm asymptomatic preventive use
Prior authorization requests for CAC scoring should confirm the test is being requested for an asymptomatic individual to inform preventive ASCVD risk management and specify the CT technology (eg, EBCT or spiral CT).
PA may depend on guideline-directed eligibility
Prior authorization eligibility may hinge on guideline-directed criteria—different risk calculators (eg, ACC/AHA pooled cohort, PREVENT, ESC/EAS) identify different subsets of patients eligible for CAC scanning.
PA applies for CAC CT in chest pain evaluation
Prior authorization is required when CAC scoring with CT (including EBCT or spiral CT) is requested to evaluate persistent stable angina or new acute chest pain and when the result will be used to guide the diagnostic pathway.
AI-based CAC results are adjunctive to clinician review
AI-based CAC detection methods are intended as adjunctive information to clinician interpretation for adults undergoing noncontrast ECG‑gated or non‑ECG‑gated chest CT and should not replace physician review.
No specified PA for incidental or AI-detected CAC
The policy does not specify prior-authorization requirements for incidental CAC detection on noncontrast, non‑ECG‑gated chest CT or for use of AI algorithms; FDA-cleared AI CAC algorithms are described as adjunctive tools.
Medicare: no national coverage determination
There is no national Medicare coverage determination for CAC scoring; coverage and any prior-authorization requirements are left to local Medicare carriers.
Submit imaging and diagnosis codes with clinical indication
When requesting coverage for CAC scoring, submit the appropriate imaging CPT/HCPCS and ICD-10 codes along with the clinical indication; inclusion of codes does not guarantee coverage and determinations remain subject to member benefits.
Risk‑stratified use before ordering CAC
CAC scoring is intended as an adjunct for primary prevention decision-making in patients with borderline-to-intermediate 10‑year ASCVD risk and who are not on lipid‑lowering therapy; clinicians should use PREVENT‑ASCVD or similar inputs to determine risk category before ordering CAC.
Order CAC to supplement traditional risk assessment
Consider CAC testing after traditional risk stratification (eg, Framingham or pooled‑cohort approaches); CAC is used to reclassify risk and guide management rather than as a first‑line standalone test.
CAC results may change preventive medication use
CAC results have been associated with initiation or continuation of preventive pharmacotherapies such as aspirin, lipid‑lowering, and blood‑pressure lowering medications; document how CAC influenced pharmacotherapy decisions.
CAC can serve as adjunct/triage in diagnostic pathways
CAC scoring can be positioned as an alternative or adjunct to standard diagnostic testing (functional testing, exercise ECG) and may be used for triage strategies—e.g., CAC scanning followed by CCTA if CAC > 0.
CAC‑guided triage thresholds reported in observational algorithms
In some observational algorithms used in chest‑pain clinics, CAC thresholds were used to triage further testing (example: CAC ≥1000 → invasive coronary angiography; CAC <1000 → CCTA).
- Example triage thresholds used in studies: CAC ≥1000 → invasive angiography; CAC <1000 → CCTA
No formal step‑therapy requirements specified
No step‑therapy sequencing requirements are described in the policy; randomized trials assessed the effect of clinician/patient notification on statin initiation but did not define step‑therapy pathways.
Document CAC influence on lipid‑lowering therapy
When CAC is used to guide lipid‑lowering therapy, providers should document how the CAC result influenced initiation or intensity of lipid‑lowering therapy decisions.
Required documentation: modality and intended use
Documentation should demonstrate that CAC scoring was performed using fast CT (EBCT or spiral CT) and should show that the scan was used to modify preventive cardiac risk‑reduction interventions in an asymptomatic individual.
Document downstream testing and management by CAC strata
Reports of downstream testing and interventions differed by CAC strata; document patient risk status, CAC result, and subsequent management decisions to support utilization and coverage determinations.
Required clinical documentation for chest‑pain evaluations
Clinical documentation should support CAC scoring with CT (EBCT or spiral CT) when used for evaluation of persistent stable angina or acute chest pain and reference patient selection consistent with study criteria.
Study‑level documentation requirements for AI CAC
Studies evaluating AI‑based CAC scoring must report the marketed version of the technology, include a suitable reference standard, describe patient/sample clinical characteristics and selection criteria, and report on at least 100 patients.
Document clinician/patient notification and physician review for AI detection
When AI‑detected incidental CAC on non‑gated chest CT is reported in studies, documentation included clinician‑and‑patient notification and tracking of statin prescriptions and discussions; FDA‑cleared algorithms are adjunctive and require physician review.
Document incidental CAC severity or Agatston score
Guidelines recommend reporting at least a qualitative interpretation of incidental CAC on noncardiac chest CT (none, mild, moderate, severe) and considering referral or primary prevention when CAC is severe; include CAC severity or Agatston score when available.
Include specific codes and clinical indication with requests
Include the specific CPT/HCPCS/ICD‑10 codes and the clinical indication on the request to support medical necessity; code guidance is provided in the policy but does not guarantee coverage.
Investigational: AI‑based automated CAC analysis
Requests for AI‑based automated detection, quantification, or scoring of coronary artery calcium are considered investigational and would be denied if submitted as the requested service.
Investigational: other indications
Computed tomography to detect coronary artery calcification for indications other than the specified asymptomatic, age ≥40, borderline‑to‑intermediate ASCVD risk population is investigational and may be denied.
Denial risk: insufficient study evidence (min 1,000 patients)
Studies considered adequate for clinical validity reporting required at least 1,000 patients and clear description of the marketed technology, reference standard, clinical characteristics, and selection criteria; absence of these elements could trigger denial for insufficient evidence.
Denial risk: trial limitations and variable downstream testing
Limitations and differential dropout in trials reduce certainty of benefit, and downstream testing/resource use varied by CAC score (normal vs ≥400); these factors may influence utilization decisions and potential denials.
Denial risk: evidence eligibility influences coverage
Coverage eligibility for study evidence required reporting of the marketed version of the technology, suitable reference standard, described clinical characteristics and selection criteria, and a minimum sample size; failure to meet these requirements can affect coverage decisions.
Denial risk: CAC not established for symptomatic patients
Because clinical validity of CAC scoring for symptomatic patients has not been established, requests relying on CAC alone to rule out CAD in symptomatic individuals may be denied or considered not medically necessary.
No explicit PA or coding denial triggers listed
The provided text does not specify explicit procedural authorization, prior authorization, or coding denial triggers.
Plan‑level variability and Essential Health Benefits
States define Essential Health Benefits for fully insured non‑grandfathered plans; plan‑level variability in benefits and administrative rules may affect coverage decisions for CAC testing.
Investigational indications may be denied
Requests for computed tomography to detect coronary artery calcification for indications other than the covered adjunctive use in asymptomatic adults age ≥40 with borderline‑to‑intermediate 10‑year risk may be denied as investigational.
AI‑based CAC detection considered investigational
Use of AI‑based automated detection, quantification, or scoring of CAC on chest CT (gated or non‑gated) is considered investigational and may be denied if submitted as the requested service.
Background
Coronary artery calcium detected on CT correlates with the presence and burden of coronary atherosclerosis and provides prognostic information about future coronary events. CAC scoring (Agatston method) can reclassify risk beyond traditional calculators and has been used to guide primary prevention decisions such as initiation or deferral of lipid‑lowering therapy. Opportunistic assessment on non‑ECG‑gated chest CT can identify subclinical atherosclerosis without additional imaging, though prognostic and diagnostic performance vary by acquisition technique and reference standard.
Definitions
Revision History
Policy statements updated to specify that coronary artery calcium scoring may be medically necessary as an adjunct to standard cardiovascular risk assessment in asymptomatic adults ≥40 years with borderline-to-intermediate 10-year ASCVD risk; AI-based automated detection/quantification/scoring of CAC on chest CT is stated investigational; CT to detect CAC for other indications is investigational.
Policy updated with literature review through July 14, 2025; references added; policy statements unchanged.
Policy updated with literature review through July 11, 2024; no references added; policy statements unchanged.
Policy updated with literature review through July 27, 2023; no references added; policy statements unchanged.
Policy updated with literature review through July 18, 2022; references added; policy statements unchanged.
Policy replaced and updated with literature review through July 28, 2021; reference added; policy statements unchanged.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.